[Ãëàâíàÿ/Ïîèñê] [Ïðîèçâîäèòåëè] [Ìîñêâà] [Ñ-Ïá] [Äðóãèå] [Îáùèé] [Âûáîðêà]

Öåíû íà ÑÀÁ ÑÈÌÏËÅÊÑ ÑÓÑÏ - ÑÛÂÎÐÎÒÊÀ Ñ ÝÊÑÒÐ. ÏËÀÖ

Ïðîäàâåö: ÐÎÑÔÀÐÌÀÖÈß (Ìîñêâà, Ðåóòîâ, óë.Ôàáðè÷íàÿ ä.7 Òåë./ôàêñ:(495) 926-36-87 (495) 926-90-66)

ÍàèìåíîâàíèåÏðîèçâîäèòåëüÖåíà $Öåíà ðóá
ÑÀÁ ÑÈÌÏËÅÊÑ ÑÓÑÏ.Ä/ÂÍÓÒÐ.ÏÐÈÌ. 69,19ÌÃ/ÌË 30ÌË ¹1 (PFIZER, ÔÐÀÍÖÈß)PFIZER165.61
ÑÀÁÅËÜÍÈÊ ÊÐÅÌ Ä/ÒÅËÀ 75ÌË (ÔÎÐÀ-ÔÀÐÌ/ÊÎÐÎËÅÂ ÔÀÐÌ, ÐÎÑÑÈß)ÔÎÐÀ-ÔÀÐÌ/ÊÎÐÎËÅÂ ÔÀÐÌ52.93
ÑÀÁÅËÜÍÈÊ-ÝÂÀËÀÐ ÊÐÅÌ 100ÌË (ÝÂÀËÀÐ, ÐÎÑÑÈß)ÝÂÀËÀÐ56.63
ÑÀÁÅËÜÍÈÊ-ÝÂÀËÀÐ Í-ÊÀ 50ÌË (ÝÂÀËÀÐ, ÐÎÑÑÈß)ÝÂÀËÀÐ45.6
ÑÀÁÅËÜÍÈÊ-ÝÂÀËÀÐ ÒÀÁ. 500ÌÃ ¹60 (ÝÂÀËÀÐ, ÐÎÑÑÈß)ÝÂÀËÀÐ64.81
ÑÀÁÅËÜÍÈÊ-ÝÂÀËÀÐ ×ÀÉ 50à (ÝÂÀËÀÐ, ÐÎÑÑÈß)ÝÂÀËÀÐ24.33
ÑÀËÀÌÎË ÝÊÎ ÀÝÐÎÇÎËÜ 100ÌÊÃ/ÄÎÇÀ 200ÄÎÇ ¹1 (IVAX-CR/NORTON, ÈÐËÀÍÄÈß)IVAX-CR/NORTON103.07
ÑÀËÈÍ ÑÏÐÅÉ ÍÀÇ. 30ÌË ¹1 (SAGMEL INÑ, ÑØÀ)SAGMEL INÑ106.32
ÑÀËÈÍ ÑÏÐÅÉ ÍÀÇ. 30ÌË ¹1 (SAGMEL INÑ/INSTITUTO DE ANGELI, ÈÒÀËÈß)SAGMEL INÑ/INSTITUTO DE ANGELI98.5
ÑÀËÈÖÈËÎÂÀß ÊÈÑËÎÒÀ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ.ÑÏÈÐÒ. 1% 40ÌË ¹1 (ÉÎÄÍÛÅ ÒÅÕÍÎËÎÃÈÈ È ÌÀÐÊÅÒÈÍÃ, ÐÎÑÑÈß)ÉÎÄÍÛÅ ÒÅÕÍÎËÎÃÈÈ È ÌÀÐÊÅÒÈÍÃ10.19
ÑÀËÈÖÈËÎÂÀß ÊÈÑËÎÒÀ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ.ÑÏÈÐÒ. 2% 40ÌË ¹1 (ÉÎÄÍÛÅ ÒÅÕÍÎËÎÃÈÈ È ÌÀÐÊÅÒÈÍÃ, ÐÎÑÑÈß)ÉÎÄÍÛÅ ÒÅÕÍÎËÎÃÈÈ È ÌÀÐÊÅÒÈÍÃ10.69
ÑÀËÎÔÀËÜÊ ÑÓÏÏ. ÐÅÊÒÀËÜÍÛÅ 500ÌÃ ¹10 (DR. FALK PHARMA, ÃÅÐÌÀÍÈß)DR. FALK PHARMA606.84
ÑÀËÎÔÀËÜÊ ÒÀÁ. 250ÌÃ ¹50 (DR. FALK PHARMA, ÃÅÐÌÀÍÈß)DR. FALK PHARMA757.65
ÑÀËÎÔÀËÜÊ ÒÀÁ. 500ÌÃ ¹50 (DR. FALK PHARMA, ÃÅÐÌÀÍÈß)DR. FALK PHARMA1280.24
ÑÀËÔÅÒÊÀ ÀÍÒÈÑÅÏÒÈ×ÅÑÊÀß ÑÏÈÐÒÎÂÀß 135ÌÌX185ÌÌ ¹1 (Ì.Ê. ÀÑÅÏÒÈÊÀ, ÐÎÑÑÈß)Ì.Ê. ÀÑÅÏÒÈÊÀ1.73
ÑÀËÔÅÒÊÀ ÀÍÒÈÑÅÏÒÈ×ÅÑÊÀß ÑÏÈÐÒÎÂÀß Ä/ÈÍ 30ÌÌ Õ 60ÌÌ ¹1 (Ì.Ê. ÀÑÅÏÒÈÊÀ, ÐÎÑÑÈß)Ì.Ê. ÀÑÅÏÒÈÊÀ0.41
ÑÀËÔÅÒÊÀ ÀÍÒÈÑÅÏÒÈ×ÅÑÊÀß ÑÏÈÐÒÎÂÀß Ä/ÈÍ ¹1 6Õ10ÑÌ ¹1 (Ì.Ê. ÀÑÅÏÒÈÊÀ, ÐÎÑÑÈß)Ì.Ê. ÀÑÅÏÒÈÊÀ0.74
ÑÀËÔÅÒÊÈ JAMAICA ÎÄÍÎÑË. Ñ ÐÈÑÓÍÊÎÌ ¹50 (ÁÓÌÔÀ ÃÐÓÏÏ, ÐÎÑÑÈß)ÁÓÌÔÀ ÃÐÓÏÏ13.29
ÑÀËÔÅÒÊÈ PREMIAL ÂË. Ä/ÄÅÒÑÊ. ÃÈÃ. Ñ ÀËÎÅ-ÂÅÐÀ ¹20 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ20.42
ÑÀËÔÅÒÊÈ PREMIAL ÂËÀÆ. ÀÍÒÈÁÀÊÒÅÐ Ä/ØÊÎËÜÍÈÊÎÂ ¹15 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ14.29
ÑÀËÔÅÒÊÈ PREMIAL ÂËÀÆÍÛÅ ÀÍÒÈÁÀÊÒÅÐÈÀËÜÍÛÅ ¹15 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ13.57
ÑÀËÔÅÒÊÈ PREMIAL ÂËÀÆÍÛÅ Ä/ÈÍÒÈÌ.ÃÈÃÈÅÍÛ Ñ ÌÎËÎ×.ÊÈÑËÎÒÎÉ ¹20 (ÁÓÌÔÀ ÃÐÓÏÏ, ÐÎÑÑÈß)ÁÓÌÔÀ ÃÐÓÏÏ21.12
ÑÀËÔÅÒÊÈ PREMIAL ÂËÀÆÍÛÅ Î×ÈÙ.(4 ÀÐÎÌÀÒÀ) ¹15 ÀÊÖÈß "ÏËÀÒÎ×ÅÊ Â ÏÎÄÀÐÎÊ" (ÁÓÌÔÀ ÃÐÓÏÏ, ÐÎÑÑÈß)ÁÓÌÔÀ ÃÐÓÏÏ13.69
ÑÀËÔÅÒÊÈ PREMIAL Ä/ÄÅÒÑÊ ÃÈÃ. Î×ÈÙ.ÊÐÅÌÎÂÛÅ ¹10 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ17.43
ÑÀËÔÅÒÊÈ PREMIAL Ä/ÄÅÒÑÊ ÃÈÃ. Î×ÈÙ.ÊÐÅÌÎÂÛÅ ¹20 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ30.88
ÑÀËÔÅÒÊÈ PREMIAL Ä/ÄÅÒÑÊÎÉ ÃÈÃÈÅÍÛ ÍÅÀÐÎÌÀÒÈÇ. ¹40 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ35.45
ÑÀËÔÅÒÊÈ PREMIAL Ä/ÄÅÒÑÊÎÉ ÃÈÃÈÅÍÛ Ñ ÀËÎÅ-ÂÅÐÀ ¹10 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ13.17
ÑÀËÔÅÒÊÈ PREMIAL Ä/ÄÅÒÑÊÎÉ ÃÈÃÈÅÍÛ Ñ ÀËÎÅ-ÂÅÐÀ ¹80 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ66.66
ÑÀËÔÅÒÊÈ PREMIAL Ä/ÈÍÒÈÌÍÎÉ ÃÈÃÈÅÍÛ ÆÅÍ. ¹10 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ13.17
ÑÀËÔÅÒÊÈ PREMIAL Ä/ÈÍÒÈÌÍÎÉ ÃÈÃÈÅÍÛ ÆÅÍ. ¹20 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ21.6
ÑÀËÔÅÒÊÈ PREMIAL Ä/ÑÍßÒÈß ÌÀÊÈ߯À ¹20 (ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÁÓÌÀÆÍÀß ÔÀÁÐÈÊÀ20.39
ÑÀËÔÅÒÊÈ ÌÀÐËÅÂÛÅ ÑÒÅÐ. 16Õ14 ¹10 (ÄÂÓÕÑËÎÉÍÛÅ) (ÌÅÄÊÎÌÏÐÅÑÑ ÏËÞÑ, ÐÎÑÑÈß)ÌÅÄÊÎÌÏÐÅÑÑ ÏËÞÑ7.77
ÑÀËÔÅÒÊÈ ÌÀÐËÅÂÛÅ ÑÒÅÐ. 16Õ14 ¹20 (ÄÂÓÕÑËÎÉÍÛÅ) (ÌÅÄÊÎÌÏÐÅÑÑ ÏËÞÑ, ÐÎÑÑÈß)ÌÅÄÊÎÌÏÐÅÑÑ ÏËÞÑ13.4
ÑÀËÔÅÒÊÈ ÌÀÐËÅÂÛÅ ÑÒÅÐ. 45Õ29 ¹5 (ÄÂÓÕÑËÎÉÍÛÅ) (ÌÅÄÊÎÌÏÐÅÑÑ ÏËÞÑ, ÐÎÑÑÈß)ÌÅÄÊÎÌÏÐÅÑÑ ÏËÞÑ17.07
ÑÀËÔÅÒÊÈ ÌÀÐËÅÂÛÅ ÑÒÅÐ. 45Õ29 ¹5 (ÄÂÓÕÑËÎÉÍÛÅ) (ÍÀÂÒÅÊÑ, ÐÎÑÑÈß)ÍÀÂÒÅÊÑ15.21
ÑÀËÜÁÓÒÀÌÎË ÀÝÐÎÇÎËÜ 12ÌË 200ÄÎÇ ¹1 (ÀËÒÀÉÂÈÒÀÌÈÍÛ ÇÀÎ, ÐÎÑÑÈß)ÀËÒÀÉÂÈÒÀÌÈÍÛ ÇÀÎ50.74
ÑÀËÜÁÓÒÀÌÎË ÀÝÐÎÇÎËÜ 12ÌË ¹1 (ÌÎÑÕÈÌÔÀÐÌÏÐÅÏÀÐÀÒÛ, ÐÎÑÑÈß)ÌÎÑÕÈÌÔÀÐÌÏÐÅÏÀÐÀÒÛ73.2
ÑÀËÜÃÈÌ Ð-Ð Ä/ÈÍÃ. 1ÌÃ/ÌË 10ÌË ¹10 (ÏÓËÜÌÎÌÅÄ, ÐÎÑÑÈß)ÏÓËÜÌÎÌÅÄ217.04
ÑÀËÜÒÎÑ ÒÀÁ. 7,23ÌÃ ¹30 (ÏÓËÜÌÎÌÅÄ, ÐÎÑÑÈß)ÏÓËÜÌÎÌÅÄ180.16
ÑÀÍÂÀË ÒÀÁ. Ï/Î 10ÌÃ ¹10 (LEK D.D., ÑËÎÂÅÍÈß)LEK D.D.168.61
ÑÀÍÂÀË ÒÀÁ. Ï/Î 10ÌÃ ¹20 (LEK, ÑËÎÂÅÍÈß)LEK231.37
ÑÀÍÃÂÈÐÈÒÐÈÍ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ.ÑÏÈÐÒ. 0,2% 50ÌË ¹1 (ÂÈËÀÐ, ÐÎÑÑÈß)ÂÈËÀÐ57.63
ÑÀÍÄÎÑÒÀÒÈÍ Ð-Ð Ä/ÈÍ. 0,05ÌÃ/ÌË 1ÌË ¹5 (NOVARTIS PHARMA, ØÂÅÉÖÀÐÈß)NOVARTIS PHARMA1355.97
ÑÀÍÄÐÀ ÒÀÁ. ÃÎÌÅÎÏ. 250ÌÃ ¹30 (ÂÈËÀÐ, ÐÎÑÑÈß)ÂÈËÀÐ61.67
ÑÀÍÎÐÈÍ ÊÀÏËÈ ÍÀÇ. 0,05% 10ÌË ¹1 (IVAX-CR, ×ÅÕÈß)IVAX-CR40.86
ÑÀÍÎÐÈÍ ÊÀÏËÈ ÍÀÇ. 0,1% 10ÌË ¹1 (IVAX-CR, ×ÅÕÈß)IVAX-CR49.61
ÑÀÍÎÐÈÍ Ñ ÌÀÑËÎÌ ÝÂÊÀËÈÏÒÀ ÝÌÓËÜÑÈß 0,1% 10ÌË ¹1 ÔË. (IVAX PHARMACEUTICALS, ×ÅÕÈß)IVAX PHARMACEUTICALS52.61
ÑÀÍÎÐÈÍ ÑÏÐÅÉ ÍÀÇ. 0,1% 10ÌË ¹1 (IVAX-CR, ×ÅÕÈß)IVAX-CR78.48
ÑÀÐÈÄÎÍ ÒÀÁ. ¹10 (BAYER SANTE FAMILIALE, ÔÐÀÍÖÈß)BAYER SANTE FAMILIALE104.97
ÑÅÀËÅÊÑ ÔÎÐÒÅ ÊÀÏÑ. 400ÌÃ ¹12 (ÂÈÑ ÎÎÎ, ÐÎÑÑÈß)ÂÈÑ ÎÎÎ696.14
ÑÅÀËÅÊÑ ÔÎÐÒÅ ÊÀÏÑ. 400ÌÃ ¹12 (ÃÍÖ ÏÌ ÔÀÐÌÀ, ÐÎÑÑÈß)ÃÍÖ ÏÌ ÔÀÐÌÀ933.06
ÑÅÁÈÄÈÍ ÒÀÁ. ¹20 (GLAXO SMITH KLINE, ÏÎËÜØÀ)GLAXO SMITH KLINE56.39
ÑÅÁÎÇÎË ØÀÌÏÓÍÜ ÎÒ ÏÅÐÕÎÒÈ 100ÌË (ÄÈÎÍÈÑ ÎÎÎ, ÐÎÑÑÈß)ÄÈÎÍÈÑ ÎÎÎ195.81
ÑÅÁÎÇÎË ØÀÌÏÓÍÜ ÎÒ ÏÅÐÕÎÒÈ 5ÌË ¹5 (ÄÈÎÍÈÑ ÎÎÎ, ÐÎÑÑÈß)ÄÈÎÍÈÑ ÎÎÎ77.31
ÑÅÄÀË-Ì ÒÀÁ. ¹10 (MILVE PHARMACEUTICALS JSC, ÁÎËÃÀÐÈß)MILVE PHARMACEUTICALS JSC42.05
ÑÅÄÀË-Ì ÒÀÁ. ¹20 (MILVE PHARMACEUTICALS JSC, ÁÎËÃÀÐÈß)MILVE PHARMACEUTICALS JSC84.2
ÑÅÄÀËÈÒ ÒÀÁ. 300ÌÃ ¹50 (ÔÀÐÌÑÒÀÍÄÀÐÒ-ËÅÊÑÐÅÄÑÒÂÀ, ÐÎÑÑÈß)ÔÀÐÌÑÒÀÍÄÀÐÒ-ËÅÊÑÐÅÄÑÒÂÀ77.19
ÑÅÄÀËÜÃÈÍ-ÍÅÎ ÒÀÁ. ¹10 (BALKANPHARMA, ÁÎËÃÀÐÈß)BALKANPHARMA61.99
ÑÅËÅÍÀÇÀ Ð-Ð Ä/ÈÍ. 50ÌÊÃ/ÌË 10ÌË ¹10 (VASSERBURGER ARTZNEIMITTELVERK DR. MADAUS, ÃÅÐÌÀÍÈß)VASSERBURGER ARTZNEIMITTELVERK DR. MADAUS3013.5
ÑÅËÌÅÂÈÒ ÒÀÁ. Ï/Î ¹30 (ÓÔÀÂÈÒÀ, ÐÎÑÑÈß)ÓÔÀÂÈÒÀ89.91
ÑÅËÌÅÂÈÒ ÒÀÁ. Ï/Î ¹60 (ÓÔÀÂÈÒÀ, ÐÎÑÑÈß)ÓÔÀÂÈÒÀ122.06
ÑÅËÌÅÂÈÒ ÒÀÁ. Ï/Î ¹60 (ÔÀÐÌÑÒÀÍÄÀÐÒ-ÓÔÀÂÈÒÀ, ÐÎÑÑÈß)ÔÀÐÌÑÒÀÍÄÀÐÒ-ÓÔÀÂÈÒÀ126.87
ÑÅÌÀÊÑ ÊÀÏËÈ 0,1% 3ÌË ¹1 (ÏÅÏÒÎÃÅÍ, ÐÎÑÑÈß)ÏÅÏÒÎÃÅÍ318.43
ÑÅÌÀÊÑ ÊÀÏËÈ 1% 3ÌË ¹1 (ÏÅÏÒÎÃÅÍ, ÐÎÑÑÈß)ÏÅÏÒÎÃÅÍ1645.2
ÑÅÍÀÄÅ ÒÀÁ. ¹500 (CIPLA, ÈÍÄÈß)CIPLA511.61
ÑÅÍÍÛ ËÈÑÒÜß 1,5à ¹20 Ô/ÏÀÊ. (ÈÂÀÍ-×ÀÉ ÇÀÎ, ÐÎÑÑÈß)ÈÂÀÍ-×ÀÉ ÇÀÎ24.41
ÑÅÍÍÛ ËÈÑÒÜß 1,5Ã ¹20 Ô/ÏÀÊ. (ÊÐÀÑÍÎÃÎÐÑÊËÅÊÑÐÅÄÑÒÂÀ ÎÀÎ, ÐÎÑÑÈß)ÊÐÀÑÍÎÃÎÐÑÊËÅÊÑÐÅÄÑÒÂÀ ÎÀÎ34.44
ÑÅÍÍÛ ËÈÑÒÜß 1,5Ã ¹20 Ô/ÏÀÊ. (ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ, ÐÎÑÑÈß)ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ19.05
ÑÅÍÍÛ ËÈÑÒÜß 50à ¹1 (ÈÂÀÍ-×ÀÉ ÇÀÎ, ÐÎÑÑÈß)ÈÂÀÍ-×ÀÉ ÇÀÎ17.68
ÑÅÍÍÛ ÝÊÑÒÐÀÊÒ ÒÀÁ. 300ÌÃ ¹10 (ÂÈÔÈÒÅÕ ÇÀÎ, ÐÎÑÑÈß)ÂÈÔÈÒÅÕ ÇÀÎ8.23
ÑÅÏÒÎÃÀË ÒÀÁ. ¹20 (JADRAN, ÕÎÐÂÀÒÈß)JADRAN39.29
ÑÅÏÒÎËÅÒÅ Ä ÏÀÑÒÈËÊÈ Á/ÑÀÕ. ¹30 (KRKA, ÑËÎÂÅÍÈß)KRKA51.19
ÑÅÏÒÎËÅÒÅ ÍÅÎ ÏÀÑÒÈËÊÈ 1,2ÌÃ ¹18 (ËÈÌÎÍ) (KRKA, ÑËÎÂÅÍÈß)KRKA58.11
ÑÅÏÒÎËÅÒÅ ÍÅÎ ÏÀÑÒÈËÊÈ 1,2ÌÃ ¹18 (ËÈÌÎÍ) (KRKA- ÐÓÑ, ÑËÎÂÅÍÈß)KRKA- ÐÓÑ62.34
ÑÅÏÒÎËÅÒÅ ÍÅÎ ÏÀÑÒÈËÊÈ 1,2Ìà ¹18 (×ÅÐÅØÍß) (KRKA, ÑËÎÂÅÍÈß)KRKA62.29
ÑÅÏÒÎËÅÒÅ ÍÅÎ ÏÀÑÒÈËÊÈ 1,2Ìà ¹18 (ßÁËÎÊÎ) (KRKA, ÑËÎÂÅÍÈß)KRKA58.17
ÑÅÏÒÎËÅÒÅ ÏÀÑÒÈËÊÈ ¹30 (KRKA, ÑËÎÂÅÍÈß)KRKA64.25
ÑÅÏÒÎËÅÒÅ ÏËÞÑ ÏÀÑÒÈËÊÈ ¹18 (KRKA, ÑËÎÂÅÍÈß)KRKA67.84
ÑÅÐÅÒÈÄ ÀÝÐÎÇÎËÜ 0,25ÌÃ/125ÌÊÃ 120ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÏÎËÜØÀ)GLAXO SMITH KLINE1361.6
ÑÅÐÅÒÈÄ ÀÝÐÎÇÎËÜ 0,25ÌÃ/250ÌÊÃ 120ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÏÎËÜØÀ)GLAXO SMITH KLINE2078.42
ÑÅÐÅÒÈÄ ÀÝÐÎÇÎËÜ 0,25ÌÃ/50ÌÊÃ 120ÄÎÇ ¹1 (GLAXO SMITH KLINE)GLAXO SMITH KLINE1044.89
ÑÅÐÅÒÈÄ ÌÓËÜÒÈÄÈÑÊ ÏÎÐ.Ä/ÈÍÃ.ÄÎÇÈÐ. 50ÌÊÃ/0,1ÌÃ 60ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÂÅËÈÊÎÁÐÈÒÀÍÈß)GLAXO SMITH KLINE1106.11
ÑÅÐÅÒÈÄ ÌÓËÜÒÈÄÈÑÊ ÏÎÐ.Ä/ÈÍÃ.ÄÎÇÈÐ. 50ÌÊÃ/0,25ÌÃ 60ÄÎÇ ¹1 (GLAXO SMITH KLINE, ÂÅËÈÊÎÁÐÈÒÀÍÈß)GLAXO SMITH KLINE1457.87
ÑÅÐÌÈÎÍ ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍ. 4ÌÃ ¹4 Ñ Ð-ËÅÌ (PHARMACIA ITALIA, ÈÒÀËÈß)PHARMACIA ITALIA881.08
ÑÅÐÌÈÎÍ ÒÀÁ. Ï/Î 10ÌÃ ¹50 (PHARMACIA ITALIA, ÈÒÀËÈß)PHARMACIA ITALIA280.02
ÑÅÐÌÈÎÍ ÒÀÁ. Ï/Î 5ÌÃ ¹30 (PHARMACIA ITALIA, ÈÒÀËÈß)PHARMACIA ITALIA150.29
ÑÅÐÍÀß ÌÀÇÜ ÏÐÎÑÒÀß 25Ã ¹1 (ÒÂÅÐÑÊÀß ÔÀÐÌÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÒÂÅÐÑÊÀß ÔÀÐÌÔÀÁÐÈÊÀ6.57
ÑÅÐÎÊÂÅËÜ ÒÀÁ. Ï/Î 100ÌÃ ¹60 (ASTRA ZENECA, ÂÅËÈÊÎÁÐÈÒÀÍÈß)ASTRA ZENECA2838.59
ÑÅÐÎÊÂÅËÜ ÒÀÁ. Ï/Î 200ÌÃ ¹60 (ASTRA ZENECA, ÂÅËÈÊÎÁÐÈÒÀÍÈß)ASTRA ZENECA3647.05
ÑÅÐÎÊÂÅËÜ ÒÀÁ. Ï/Î 25ÌÃ ¹60 (ASTRA ZENECA, ÂÅËÈÊÎÁÐÈÒÀÍÈß)ASTRA ZENECA1503.67
ÑÅÒÅÃÈÑ ÒÀÁ. 2ÌÃ ¹30 (EGIS, ÂÅÍÃÐÈß)EGIS347.62
ÑÅÒÅÃÈÑ ÒÀÁ. 5ÌÃ ¹30 (EGIS, ÂÅÍÃÐÈß)EGIS652.48
ÑÈÀËÈÑ ÒÀÁ. Ï/Î 20ÌÃ ¹1 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß)ELI LILLY536.8
ÑÈÀËÈÑ ÒÀÁ. Ï/Î 20ÌÃ ¹2 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß)ELI LILLY983.05
ÑÈÀËÈÑ ÒÀÁ. Ï/Î 20ÌÃ ¹4 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß)ELI LILLY1874.71
ÑÈÁÀÇÎÍ ÒÀÁ. 5ÌÃ ¹20 (ÌÎÑÊÎÂÑÊÈÉ ÝÍÄÎÊÐÈÍÍÛÉ ÇÀÂÎÄ, ÐÎÑÑÈß)ÌÎÑÊÎÂÑÊÈÉ ÝÍÄÎÊÐÈÍÍÛÉ ÇÀÂÎÄ12.78
ÑÈÁÀÇÎÍ ÒÀÁ. 5ÌÃ ¹20 (ÎÐÃÀÍÈÊÀ, ÐÎÑÑÈß)ÎÐÃÀÍÈÊÀ11.11
ÑÈÁÅÊÒÀÍ ÒÀÁ. ¹30 (ÔÀÐÌÖÅÍÒÐ ÂÈËÀÐ, ÐÎÑÑÈß)ÔÀÐÌÖÅÍÒÐ ÂÈËÀÐ64.62
ÑÈÄÍÎÔÀÐÌ ÒÀÁ. 2ÌÃ ¹30 (SOPHARMA, ÁÎËÃÀÐÈß)SOPHARMA67.41
ÑÈËÅÑÒ ÒÀÁ. ¹21 (JANSSEN CILAG, ØÂÅÉÖÀÐÈß)JANSSEN CILAG252.97
ÑÈËÈÊÎÍÎÂÀß ÑÎÑÊÀ Ð.M 2ØÒ. (ÌÅÄÅËÀ, ØÂÅÉÖÀÐÈß)ÌÅÄÅËÀ185.54
ÑÈËÈÌÀÐ ÒÀÁ. 100ÌÃ ¹30 (ÂÈËÀÐ, ÐÎÑÑÈß)ÂÈËÀÐ45.03
ÑÈÌÁÀËÒÀ ÊÀÏÑ. 30ÌÃ ¹14 (ELI LILLY, ÈÑÏÀÍÈß)ELI LILLY777.87
ÑÈÌÁÀËÒÀ ÊÀÏÑ. 60ÌÃ ¹14 (ELI LILLY, ÈÑÏÀÍÈß)ELI LILLY786.86
ÑÈÌÁÀËÒÀ ÊÀÏÑ. 60ÌÃ ¹28 (ELI LILLY, ÑØÀ)ELI LILLY1693.38
ÑÈÌÁÈÊÎÐÒ ÒÓÐÁÓÕÀËÅÐ ÏÎÐÎØÎÊ 160+4,5ÌÊÃ/Ä 60ÄÎ3 ¹1 (ASTRA ZENECA, ØÂÅÖÈß)ASTRA ZENECA1215.11
ÑÈÌÁÈÊÎÐÒ ÒÓÐÁÓÕÀËÅÐ ÏÎÐÎØÎÊ 80+4,5ÌÊÃ/Ä 60ÄÎÇ ¹1 (ASTRA ZENECA, ØÂÅÖÈß)ASTRA ZENECA931.16
ÑÈÌÂÀÃÅÊÑÀË ÒÀÁ. Ï/Î 20ÌÃ ¹30 (SALUTAS PHARMA GMBH, ÃÅÐÌÀÍÈß)SALUTAS PHARMA GMBH303.97
ÑÈÌÂÀÊÀÐÄ ÒÀÁ. Ï/Î 10Ìà ¹28 (ZENTIVA/LECHIVA, ×ÅÕÈß)ZENTIVA/LECHIVA211.72
ÑÈÌÂÀÊÀÐÄ ÒÀÁ. Ï/Î 20Ìà ¹28 (ZENTIVA/LECHIVA, ×ÅÕÈß)ZENTIVA/LECHIVA140.15
ÑÈÌÂÀÑÒÀÒÈÍ ÒÀÁ. 10ÌÃ ¹30 (ÀËÑÈ ÔÀÐÌÀ, ÐÎÑÑÈß)ÀËÑÈ ÔÀÐÌÀ118.79
ÑÈÌÂÀÑÒÎË ÒÀÁ. 10ÌÃ ¹28 (GEDEON RICHTER, ÐÓÌÛÍÈß)GEDEON RICHTER207.78
ÑÈÌÂÎÐ ÒÀÁ. Ï/Î 10ÌÃ ¹30 (RANBAXY, ÈÍÄÈß)RANBAXY182.94
ÑÈÌÂÎÐ ÒÀÁ. Ï/Î 20ÌÃ ¹30 (RANBAXY, ÈÍÄÈß)RANBAXY286.49
ÑÈÌÃÀË ÒÀÁ. Ï/Î 10Ìà ¹28 (IVAX-CR, ×ÅÕÈß)IVAX-CR244.66
ÑÈÌÃÀË ÒÀÁ. Ï/Î 10Ìà ¹84 (IVAX-CR, ×ÅÕÈß)IVAX-CR575.98
ÑÈÌÃÀË ÒÀÁ. Ï/Î 20Ìà ¹28 (IVAX-CR, ×ÅÕÈß)IVAX-CR334.34
ÑÈÌÃÀË ÒÀÁ. Ï/Î 20Ìà ¹84 (IVAX-CR, ×ÅÕÈß)IVAX-CR745.41
ÑÈÌÃÀË ÒÀÁ. Ï/Î 40Ìà ¹28 (IVAX-CR, ×ÅÕÈß)IVAX-CR592.97
ÑÈÌËÎ ÒÀÁ. Ï/Î 10ÌÃ ¹28 (IPCA LABORATORIES, ÈÍÄÈß)IPCA LABORATORIES168.15
ÑÈÍÀÔËÀÍ ËÈÍÈÌÅÍÒ 0,025% 15Ã ¹1 (ÍÈÆÔÀÐÌ, ÐÎÑÑÈß)ÍÈÆÔÀÐÌ18.42
ÑÈÍÀÔËÀÍ ÌÀÇÜ 0,025% 15Ã ¹1 (ÌÓÐÎÌÑÊÈÉ ÏÐÈÁÎÐÎÑÒÐÎÈÒÅËÜÍÛÉ Ç-Ä, ÐÎÑÑÈß)ÌÓÐÎÌÑÊÈÉ ÏÐÈÁÎÐÎÑÒÐÎÈÒÅËÜÍÛÉ Ç-Ä9.78
ÑÈÍÃÓËßÐ ÒÀÁ. Ï/Î 10Ìà ¹14 (MERCK SHARP & DOHME, ÍÈÄÅÐËÀÍÄÛ)MERCK SHARP & DOHME898.06
ÑÈÍÅÊÎÄ ÊÀÏËÈ 5ÌÃ/ÌË 20ÌË ¹1 (NOVARTIS CONSUMER HEALTH, ØÂÅÉÖÀÐÈß)NOVARTIS CONSUMER HEALTH246.39
ÑÈÍÅÊÎÄ ÑÈÐÎÏ 1,5ÌÃ/ÌË 200ÌË ¹1 (NOVARTIS CONSUMER HEALTH, ØÂÅÉÖÀÐÈß)NOVARTIS CONSUMER HEALTH224.67
ÑÈÍÒÎÌÈÖÈÍ ÑÓÏÏ. ÂÀÃÈÍÀËÜÍÛÅ 250ÌÃ ¹10 (ÁÈÎÑÈÍÒÅÇ, ÐÎÑÑÈß)ÁÈÎÑÈÍÒÅÇ14.66
ÑÈÍÒÎÌÈÖÈÍ ÑÓÏÏ. ÂÀÃÈÍÀËÜÍÛÅ 250ÌÃ ¹10 (ÄÀËÜÕÈÌÔÀÐÌ ÎÀÎ, ÐÎÑÑÈß)ÄÀËÜÕÈÌÔÀÐÌ ÎÀÎ14.98
ÑÈÍÒÎÌÈÖÈÍÀ ËÈÍÈÌÅÍÒ ËÈÍÈÌÅÍÒ 10% 25Ã ¹1 (ÇÅËÅÍÀß ÄÓÁÐÀÂÀ, ÐÎÑÑÈß)ÇÅËÅÍÀß ÄÓÁÐÀÂÀ11.59
ÑÈÍÓÏÐÅÒ ÄÐÀÆÅ ¹50 (BIONORICA- ARZNEIMITTEL, ÃÅÐÌÀÍÈß)BIONORICA- ARZNEIMITTEL181.63
ÑÈÍÓÏÐÅÒ ÊÀÏËÈ 100ÌË ¹1 (BIONORICA- ARZNEIMITTEL, ÃÅÐÌÀÍÈß)BIONORICA- ARZNEIMITTEL175.38
ÑÈÍÓÔÎÐÒÅ ËÈÎÔ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍÒÐÀÍÀÇ.ÂÂÅÄ. 50ÌÃ ¹1 Ñ Ð-ËÅÌ (LABIANA FARMACEUTICA, ÈÑÏÀÍÈß)LABIANA FARMACEUTICA1289.14
ÑÈÎÔÎÐ 1000 ÒÀÁ. 1000ÌÃ ¹60 (BERLIN-CHEMIE, ÃÅÐÌÀÍÈß)BERLIN-CHEMIE385.51
ÑÈÎÔÎÐ 500 ÒÀÁ. 500ÌÃ ¹60 (BERLIN-CHEMIE, ÃÅÐÌÀÍÈß)BERLIN-CHEMIE224.56
ÑÈÎÔÎÐ 850 ÒÀÁ. 850ÌÃ ¹60 (BERLIN-CHEMIE, ÃÅÐÌÀÍÈß)BERLIN-CHEMIE294.58
ÑÈÐÄÀËÓÄ ÒÀÁ. 2ÌÃ ¹30 (NOVARTIS PHARMA, ÃÅÐÌÀÍÈß)NOVARTIS PHARMA204.93
ÑÈÐÄÀËÓÄ ÒÀÁ. 2ÌÃ ¹30 (NOVARTIS SAGLIK GIDA VE TARIM, ÒÓÐÖÈß)NOVARTIS SAGLIK GIDA VE TARIM202.89
ÑÈÐÄÀËÓÄ ÒÀÁ. 4ÌÃ ¹30 (NOVARTIS SAGLIK GIDA VE TARIM, ÒÓÐÖÈß)NOVARTIS SAGLIK GIDA VE TARIM301.67
ÑÈÐÄÀËÓÄ ÒÀÁ. 4ÌÃ ¹30 (NOVARTIS/SANDOZ, ÒÓÐÖÈß)NOVARTIS/SANDOZ302.39
ÑÈÐÎÏ ÇÅËÅÍÎÃÎ ×Àß 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ45.77
ÑÈÐÎÏ ÊËÞÊÂÀ ÍÀ ÔÐÓÊÒÎÇÅ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ55.32
ÑÈÐÎÏ ÌÀËÈÍÀ ÍÀ ÔÐÓÊÒÎÇÅ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ53.61
ÑÈÐÎÏ ÎÁËÅÏÈÕÀ ÍÀ ÔÐÓÊÒÎÇÅ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ53.71
ÑÈÐÎÏ ÏËÎÄÎÂ ØÈÏÎÂÍÈÊÀ Ñ ËÈÌ. È ×.ÑÌÎÐÎÄÈÍÎÉ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ42.44
ÑÈÐÎÏ ÏÐÈ ÊÀØËÅ 100ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ40.18
ÑÈÐÎÏ ÏÐÈ ÏÐÎÑÒÓÄÅ 100ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ40.14
ÑÈÐÎÏ ÏÓÑÒÛÐÍÈÊÀ 100ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ12.4
ÑÈÐÎÏ ×ÅÐÍ.ÑÌÎÐÎÄÈÍÀ ÍÀ ÔÐÓÊÒÎÇÅ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ50.44
ÑÈÐÎÏ ×ÅÐÍÈÊÀ ÍÀ ÔÐÓÊÒÎÇÅ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ55.32
ÑÈÐÎÏ ×ÅÐÍÈÊÈ Ñ ÝÕÈÍÀÖÅÅÉ È ØÈÏÎÂÍÈÊÎÌ 100ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ62.5
ÑÈÐÎÏ ØÈÏÎÂÍÈÊ ÍÀ ÔÐÓÊÒÎÇÅ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ45.8
ÑÈÐÎÏ ØÈÏÎÂÍÈÊÀ 100ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ19.55
ÑÈÐÎÏ ßÃÎÄ ÂÈØÍÈ Ñ ×ÅÐÍ.ÑÌÎÐÎÄÈÍÎÉ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ46.35
ÑÈÐÎÏ ßÃÎÄ ÊËÞÊÂÛ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ46.35
ÑÈÐÎÏ ßÃÎÄ ÌÀËÈÍÛ 250ÌË (ÀÑÒÐÎÌÀÐ, ÐÎÑÑÈß)ÀÑÒÐÎÌÀÐ49.11
ÑÈÑÒÅÉÍ ÊÀÏËÈ ÃËÀÇÍÛÅ 10ÌË ¹1 (ALCON COUVEUR S.A., ÈÑÏÀÍÈß)ALCON COUVEUR S.A.264.63
ÑÈÑÒÅÌÀ ÄËß ÐÀÑÒÂÎÐÎÂ ÊD ¹1 (HUAFU, ÊÈÒÀÉ)HUAFU4.92
ÑÈÑÒÅÌÀ ÄËß ÐÀÑÒÂÎÐÎÂ ÊD ¹1 (HUAFU, ÊÈÒÀÉ)HUAFU4.92
ÑÈÑÒÅÌÀ ÄËß ÐÀÑÒÂÎÐÎÂ ÊD ¹1 (WUXI YUSHOU MEDICAL APPLIANCES, ÊÈÒÀÉ)WUXI YUSHOU MEDICAL APPLIANCES4.8
ÑÈÑÒÅÌÀ ÈÍÔÓÇ. Ä/ÏÅÐÅË. Ð-ÐÎÂ SFM ¹25 (SFM HOSPITAL GMBH, ÃÅÐÌÀÍÈß)SFM HOSPITAL GMBH 176.1
ÑÈÑÒÅÌÀ ÈÍÔÓÇ. Ä/ÏÅÐÅË. Ð-ÐÎÂ ¹1 (JIANGXI HONGDA MEDICAL EQUIPMENT GROUP, ÊÈÒÀÉ)JIANGXI HONGDA MEDICAL EQUIPMENT GROUP4.86
ÑÈÑÒÅÌÀ ÈÍÔÓÇ. Ä/ÏÅÐÅË. Ð-ÐÎÂ Ñ ÏËÀÑÒ. ØÈÏÎÌ ¹1 (VOGT MEDICAL, ÃÅÐÌÀÍÈß)VOGT MEDICAL4.78
ÑÈÑÒÅÌÀ ÊÎÐÌËÅÍÈß SNS (ÌÅÄÅËÀ, ØÂÅÉÖÀÐÈß)ÌÅÄÅËÀ1122.98
ÑÈÑÒÅÌÀ ÒÐÀÍÑÔÓÇÈÎÍ. Ä/ÏÅÐÅË. ÊÐÎÂÈ SFM ¹25 (SFM HOSPITAL GMBH, ÃÅÐÌÀÍÈß)SFM HOSPITAL GMBH 119.93
ÑÈÑÒÅÌÀ ÒÐÀÍÑÔÓÇÈÎÍ. Ä/ÏÅÐÅË. ÊÐÎÂÈ SFM ¹25 (SFM HOSPITAL GMBH, ÃÅÐÌÀÍÈß)SFM HOSPITAL GMBH 257.39
ÑÈÑÒÅÌÀ ÒÐÀÍÑÔÓÇÈÎÍ. Ä/ÏÅÐÅË. ÊÐÎÂÈ Ñ ÏËÀÑÒ. ØÈÏÎÌ ¹1 (VOGT MEDICAL, ÃÅÐÌÀÍÈß)VOGT MEDICAL9.44
ÑÊÈÍ-ÊÀÏ ÀÝÐÎÇÎËÜ 0,2% 70Ã ¹1 (CHEMINOVA, ÈÑÏÀÍÈß)CHEMINOVA1657.91
ÑÊÈÍ-ÊÀÏ ÃÅËÜ Ä/ÄÓØÀ 150ÌË (CHEMINOVA, ÈÑÏÀÍÈß)CHEMINOVA361.67
ÑÊÈÍ-ÊÀÏ ÊÐÅÌ 0,2% 50Ã ¹1 (CHEMINOVA, ÈÑÏÀÍÈß)CHEMINOVA1034.89
ÑÊÈÍ-ÊÀÏ ØÀÌÏÓÍÜ 150ÌË ¹1 (CHEMINOVA, ÈÑÏÀÍÈß)CHEMINOVA658.03
ÑÊÈÍÎÐÅÍ ÃÅËÜ 15% 30Ã ¹1 (INTENDIS MANUFACTURING, ÃÅÐÌÀÍÈß)INTENDIS MANUFACTURING634.34
ÑÊÈÍÎÐÅÍ ÊÐÅÌ 20% 30Ã ¹1 (INTENDIS MANUFACTURING, ÈÒÀËÈß)INTENDIS MANUFACTURING606.09
ÑÊÈÏÀÐ ÄÂÈÆÅÍÈÅ ÝÌÓËÜÑÈß Ä/ÂÀÍÍ ÑÌÅØÀÍÍÀß 0,25Ë (ÇÅËÄÈÑ, ÐÎÑÑÈß)ÇÅËÄÈÑ190.8
ÑÊÈÏÀÐ ÑÊÈÏÈÄÀÐÍÀß ÝÌÓËÜÑÈß ÁÅËÀß 0,2Ë (Ð.ÊÎÑÌÅÒÈÊ, ÐÎÑÑÈß)Ð.ÊÎÑÌÅÒÈÊ172.74
ÑÊÈÏÀÐ ÑÊÈÏÈÄÀÐÍÀß ÝÌÓËÜÑÈß ÁÅËÀß 0,5Ë (ÇÅËÄÈÑ, ÐÎÑÑÈß)ÇÅËÄÈÑ255.27
ÑÊÈÏÀÐ ÑÊÈÏÈÄÀÐÍÛÉ Ð-Ð ÆÅËÒÛÉ 0,2Ë (Ð.ÊÎÑÌÅÒÈÊ, ÐÎÑÑÈß)Ð.ÊÎÑÌÅÒÈÊ193.2
ÑÊÈÏÀÐ ÑÊÈÏÈÄÀÐÍÛÉ Ð-Ð ÆÅËÒÛÉ 0,5Ë (ÇÅËÄÈÑ, ÐÎÑÑÈß)ÇÅËÄÈÑ299.37
ÑÊÈÏÀÐ ÒÎÍÓÑ ÝÌÓËÜÑÈß Ä/ÂÀÍÍ ÑÌÅØÀÍÍÀß 0,25Ë (ÇÅËÄÈÑ, ÐÎÑÑÈß)ÇÅËÄÈÑ184.5
ÑÊÈÏÀÐ ÔÈÃÓÐÀ ÝÌÓËÜÑÈß Ä/ÂÀÍÍ ÑÌÅØÀÍÍÀß 0,25Ë (ÇÅËÄÈÑ, ÐÎÑÑÈß)ÇÅËÄÈÑ184.5
ÑÊÈÏÈÄÀÐÍÀß ÌÀÇÜ ÌÀÇÜ 25Ã ¹1 (ÒÓËÜÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÒÓËÜÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ10.63
ÑÊÐÀÁ ÌßÃÊÈÉ Ñ ÝÊÑÒÐ.ÏËÀÖ. Ä/ÊÎÆÈ ËÈÖÀ 150ÌË (COSMEDIC LABORATORY, ÐÎÑÑÈß)COSMEDIC LABORATORY111.16
ÑÊÐÀÁ ÌßÃÊÈÉ Ñ ÝÊÑÒÐ.ÏËÀÖ. Ä/ÊÎÆÈ ËÈÖÀ 150ÌË (ÝÂÈÍÀËÜ ÎÎÎ, ÐÎÑÑÈß)ÝÂÈÍÀËÜ ÎÎÎ94.07
ÑËÀÁÈËÅÍ ÊÀÏËÈ 0,75% 15ÌË ¹1 (ËÝÍÑ-ÔÀÐÌ, ÐÎÑÑÈß)ËÝÍÑ-ÔÀÐÌ94.36
ÑËÅÇÀ ÍÀÒÓÐÀËÜÍÀß ÊÀÏËÈ ÃËÀÇÍÛÅ 15ÌË ¹1 (ALCON COUVEUR S.A., ÁÅËÜÃÈß)ALCON COUVEUR S.A.129.88
ÑÌÅÊÒÀ-ÀÏÅËÜÑÈÍ ÏÎÐÎØÎÊ 3Ã ¹10 (BEAUFOUR IPSEN, ÔÐÀÍÖÈß)BEAUFOUR IPSEN125.59
ÑÌÅÊÒÀ-ÀÏÅËÜÑÈÍ ÏÎÐÎØÎÊ 3Ã ¹30 (BEAUFOUR IPSEN, ÔÐÀÍÖÈß)BEAUFOUR IPSEN291.2
ÑÌÅÑÜ ÄËß ÈÍÃÀËßÖÈÉ Ð-Ð Ä/ÈÍÃ. 40ÌË ¹1 (ÌÎÑÊÎÂÑÊÀß ÔÀÐÌ.Ô-ÊÀ, ÐÎÑÑÈß)ÌÎÑÊÎÂÑÊÀß ÔÀÐÌ.Ô-ÊÀ7.64
ÑÎËÈÀÍ ÒÀÁ. Ï/Î 200ÌÃ ¹30 (SANOFI-WINTHROP, ÔÐÀÍÖÈß)SANOFI-WINTHROP3011.53
ÑÎËÈÀÍ ÒÀÁ. Ï/Î 400ÌÃ ¹30 (SANOFI-WINTHROP, ÔÐÀÍÖÈß)SANOFI-WINTHROP5672.1
ÑÎËÊÎÂÀÃÈÍ Ð-Ð Ä/ÌÅÑÒÍ.ÏÐÈÌ. 0,5ÌË ¹2 (VALEANT PHARMACEUTICALS, ØÂÅÉÖÀÐÈß)VALEANT PHARMACEUTICALS533.57
ÑÎËÊÎÑÅÐÈË ÃÅËÜ 10% 20Ã ¹1 (I C N SWITZERLAND, ØÂÅÉÖÀÐÈß)I C N SWITZERLAND97.54
ÑÎËÊÎÑÅÐÈË ÃÅËÜ 20Ã ¹1 (LEGACY PHARMACEUTICALS SWITZERLAND, ØÂÅÉÖÀÐÈß)LEGACY PHARMACEUTICALS SWITZERLAND95.26
ÑÎËÊÎÑÅÐÈË ÃÅËÜ ÃËÀÇÍÎÉ 20% 5Ã ¹1 (LEGACY PHARMACEUTICALS SWITZERLAND, ØÂÅÉÖÀÐÈß)LEGACY PHARMACEUTICALS SWITZERLAND168.52
ÑÎËÊÎÑÅÐÈË ÄÅÍÒÀË ÏÀÑÒÀ 5% 5Ã ¹1 (I C N SWITZERLAND, ØÂÅÉÖÀÐÈß)I C N SWITZERLAND172.59
ÑÎËÊÎÑÅÐÈË ÄÅÍÒÀË ÏÀÑÒÀ 5% 5Ã ¹1 (VALEANT PHARMACEUTICALS, ØÂÅÉÖÀÐÈß)VALEANT PHARMACEUTICALS169.77
ÑÎËÊÎÑÅÐÈË ÌÀÇÜ 5% 20Ã ¹1 (I C N SWITZERLAND, ØÂÅÉÖÀÐÈß)I C N SWITZERLAND87.25
ÑÎËÊÎÑÅÐÈË ÌÀÇÜ 5% 20Ã ¹1 (LEGACY PHARMACEUTICALS SWITZERLAND, ØÂÅÉÖÀÐÈß)LEGACY PHARMACEUTICALS SWITZERLAND89.32
ÑÎËÎÄÊÈ ÊÎÐÅÍÜ 50à ¹1 (ÈÂÀÍ-×ÀÉ ÇÀÎ, ÐÎÑÑÈß)ÈÂÀÍ-×ÀÉ ÇÀÎ16.76
ÑÎËÎÄÊÈ ÊÎÐÅÍÜ 50Ã ¹1 (ÊÐÀÑÍÎÃÎÐÑÊËÅÊÑÐÅÄÑÒÂÀ ÎÀÎ, ÐÎÑÑÈß)ÊÐÀÑÍÎÃÎÐÑÊËÅÊÑÐÅÄÑÒÂÀ ÎÀÎ25.43
ÑÎËÎÄÊÈ ÊÎÐÅÍÜ 50Ã ¹1 (ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ, ÐÎÑÑÈß)ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ14.91
ÑÎËÎÄÊÈ ÊÎÐÍÈ 50Ã ¹1 (ÇÄÎÐÎÂÜÅ, ÐÎÑÑÈß)ÇÄÎÐÎÂÜÅ19.96
ÑÎËÎÄÊÈ ÊÎÐÍß ÑÈÐÎÏ ÑÈÐÎÏ 100Ã ¹1 (ÁÝÃÐÈÔ ÎÎÎ, ÐÎÑÑÈß)ÁÝÃÐÈÔ ÎÎÎ11.67
ÑÎËÎÄÊÈ ÊÎÐÍß ÑÈÐÎÏ ÑÈÐÎÏ 100Ã ¹1 (ÑÀÌÀÐÀÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÑÀÌÀÐÀÌÅÄÏÐÎÌ10.26
ÑÎËÎÄÊÈ ÊÎÐÍß ÑÈÐÎÏ ÑÈÐÎÏ 100Ã ¹1 (ÒÂÅÐÑÊÀß ÔÀÐÌÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÒÂÅÐÑÊÀß ÔÀÐÌÔÀÁÐÈÊÀ12.78
ÑÎËÏÀÄÅÈÍ ÒÀÁ. ¹12 ÏËÀÑÒ.ÓÏ. (GLAXO SMITH KLINE, ÈÐËÀÍÄÈß)GLAXO SMITH KLINE69.45
ÑÎËÏÀÄÅÈÍ ÒÀÁ. ¹8 (GLAXO SMITH KLINE, ÈÐËÀÍÄÈß)GLAXO SMITH KLINE58.48
ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÄÓØÈÖÀ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ13.52
ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÇÂÅÐÎÁÎÉ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ14.39
ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÊÀËÅÍÄÓËÀ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ13.52
ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÊÐÀÏÈÂÀ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ13.25
ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÎÁËÅÏÈÕÀ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ14.39
ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÏÎËÛÍÜ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ14.39
ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÐÎÌÀØÊÀ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ13.52
ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ÒÛÑß×ÅËÈÑÒÍÈÊ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ14.39
ÑÎËÜ "ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ" ×ÈÑÒÎÒÅË 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ14.39
ÑÎËÜ "ÌÎÐÑÊÈÅ ÂÎÄÎÐÎÑËÈ" ËÀÌÈÍÀÐÈß 500Ã (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ15.17
ÑÎËÜ "ÌÎÐÑÊÈÅ ÂÎÄÎÐÎÑËÈ" ÔÓÊÓÑ 500Ã (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ15.17
ÑÎËÜ "ÖÂÅÒÎ×ÍÀß" ÆÀÑÌÈÍ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ13.32
ÑÎËÜ "ÖÂÅÒÎ×ÍÀß" ÐÎÇÀ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ13.32
ÑÎËÜ "ÖÂÅÒÎ×ÍÀß" ÑÈÐÅÍÜ 500à (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ13.32
ÑÎËÜ ÉÎÄÎÁÐÎÌÍÀß Ñ ÌÈÊÐÎÝËÅÌÅÍÒÀÌÈ (0,7 ÊÃ Ï/ÝÒ) (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ25.32
ÑÎËÜ ÌÎÐ. ÀÐÎÌ. ÄÓØÈÖÀ 0,5ÊÃ (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ12.52
ÑÎËÜ ÌÎÐ. ÀÐÎÌ. ËÈÌÎÍ 0,5ÊÃ (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ15.17
ÑÎËÜ ÌÎÐ. ÀÐÎÌ. ÌßÒÀ 0,5ÊÃ (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ13.2
ÑÎËÜ ÌÎÐ. ÀÐÎÌ. ÐÎÇÌÀÐÈÍ 0,5ÊÃ (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ15.17
ÑÎËÜ ÌÎÐ. ÏÐÈÐÎÄÍÀß 1ÊÃ (ÓÐÀËÌÅÄÏÐÎÌ, ÐÎÑÑÈß)ÓÐÀËÌÅÄÏÐÎÌ15.09
ÑÎÌÍÎË ÒÀÁ. Ï/Î 7,5ÌÃ ¹20 (GRINDEX, ËÀÒÂÈß)GRINDEX161.96
ÑÎÍÀÏÀÊÑ ÄÐÀÆÅ 10ÌÃ ¹60 (JELFA, ÏÎËÜØÀ)JELFA135.1
ÑÎÍÀÏÀÊÑ ÄÐÀÆÅ 25ÌÃ ¹60 (JELFA, ÏÎËÜØÀ)JELFA227.28
ÑÎÐÁÈÒ ÏÈÙÅÂÎÉ ÏÎÐÎØÎÊ 500Ã ¹1 (ÌÀÐÁÈÎÔÀÐÌ, ÐÎÑÑÈß)ÌÀÐÁÈÎÔÀÐÌ33.97
ÑÎÐÁÈÔÅÐ ÄÓÐÓËÅÑ ÒÀÁ. Ï/Î 320ÌÃ ¹30 (EGIS, ÂÅÍÃÐÈß)EGIS172.03
ÑÎÐÁÈÔÅÐ ÄÓÐÓËÅÑ ÒÀÁ. Ï/Î 320ÌÃ ¹50 (EGIS, ÂÅÍÃÐÈß)EGIS199.81
ÑÎÑÍÛ ÏÎ×ÊÈ 50à ¹1 (ÇÄÎÐÎÂÜÅ, ÐÎÑÑÈß)ÇÄÎÐÎÂÜÅ64.25
ÑÎÑÍÛ ÏÎ×ÊÈ 50à ¹1 (ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ, ÐÎÑÑÈß)ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ38.97
ÑÎÒÀÃÅÊÑÀË ÒÀÁ. 160ÌÃ ¹20 (HEXAL A.G./SALUTAS PHARMA GMBH, ÃÅÐÌÀÍÈß)HEXAL A.G./SALUTAS PHARMA GMBH134.01
ÑÎÒÀÃÅÊÑÀË ÒÀÁ. 80ÌÃ ¹20 (HEXAL A.G./SALUTAS PHARMA GMBH, ÃÅÐÌÀÍÈß)HEXAL A.G./SALUTAS PHARMA GMBH80.9
ÑÎÒÀËÅÊÑ ÒÀÁ. 160ÌÃ ¹30 (BRISTOL MYERS SQUIBB, ÔÐÀÍÖÈß)BRISTOL MYERS SQUIBB122.02
ÑÎÔÐÀÄÅÊÑ ÊÀÏËÈ 5ÌË ¹1 (AVENTIS PHARMA, ÈÍÄÈß)AVENTIS PHARMA104.24
ÑÎÔÜß (Ï×ÅËÈÍÛÉ ßÄ) ÊÐÅÌ Ä/ÒÅËÀ 75ÌË (ÔÎÐÀ-ÔÀÐÌ, ÐÎÑÑÈß)ÔÎÐÀ-ÔÀÐÌ75.93
ÑÎÔÜß (ÝÊÑÒÐÀÊÒ ÏÈßÂÊÈ) ÊÐÅÌ Ä/ÍÎà 75ÌË (ÔÎÐÀ-ÔÀÐÌ, ÐÎÑÑÈß)ÔÎÐÀ-ÔÀÐÌ77.08
ÑÏÀÇÌÀËÃÎÍ Ð-Ð Ä/ÈÍ. 2ÌË ¹10 (SOPHARMA, ÁÎËÃÀÐÈß)SOPHARMA121.11
ÑÏÀÇÌÀËÃÎÍ Ð-Ð Ä/ÈÍ. 5ÌË ¹10 (SOPHARMA, ÁÎËÃÀÐÈß)SOPHARMA157.65
ÑÏÀÇÌÀËÃÎÍ ÒÀÁ. ¹20 (BALKANPHARMA, ÁÎËÃÀÐÈß)BALKANPHARMA56.17
ÑÏÀÇÌÀËÈÍ Ð-Ð ÄËß Â/Â È Â/Ì ÂÂÅÄ. 5ÌË ¹25 (TORRENT PHARMACEUTICALS, ÈÍÄÈß)TORRENT PHARMACEUTICALS258.64
ÑÏÀÇÌÅÊÑ ÒÀÁ. 15ÌÃ ¹30 (DR. R. PFLEGER, ÃÅÐÌÀÍÈß)DR. R. PFLEGER307.41
ÑÏÀÇÌÅÊÑ ÒÀÁ. 5ÌÃ ¹30 (DR. R. PFLEGER, ÃÅÐÌÀÍÈß)DR. R. PFLEGER148.61
ÑÏÀÇÌÎË ÒÀÁ. 40ÌÃ ¹100 (ÔÀÐÌÑÒÀÍÄÀÐÒ ËÅÊÑÐÅÄÑÒÂÀ, ÐÎÑÑÈß)ÔÀÐÌÑÒÀÍÄÀÐÒ ËÅÊÑÐÅÄÑÒÂÀ69.23
ÑÏÀÇÌÎË ÒÀÁ. 40ÌÃ ¹20 (ÔÀÐÌÑÒÀÍÄÀÐÒ-ËÅÊÑÐÅÄÑÒÂÀ, ÐÎÑÑÈß)ÔÀÐÌÑÒÀÍÄÀÐÒ-ËÅÊÑÐÅÄÑÒÂÀ20.23
ÑÏÀÇÌÎÍÅÒ ÒÀÁ. 40ÌÃ ¹20 (KRKA- ÐÓÑ, ÐÎÑÑÈß)KRKA- ÐÓÑ43.11
ÑÏÀÐÔËÎ ÒÀÁ. 200ÌÃ ¹6 (DR. REDDYS LAB., ÈÍÄÈß)DR. REDDYS LAB.292.83
ÑÏÀÑÀÒÅËÜ ÁÀËÜÇÀÌ 30Ã (ËÞÌÈ, ÐÎÑÑÈß)ËÞÌÈ47.04
ÑÏÅÖÈÀËÜÍÎÅ ÄÐ. ÌÅÐÖ ÁÜÞÒÈ 675ÌÃ ¹60 (MERZ-PHARMA, ÃÅÐÌÀÍÈß)MERZ-PHARMA482.59
ÑÏÅÖÈÀËÜÍÎÅ ÄÐÀÆÅ ÌÅÐÖ ÄÐÀÆÅ 695ÌÃ ¹60 (MERZ-PHARMA, ÃÅÐÌÀÍÈß)MERZ-PHARMA414.14
ÑÏÈÐÈÂÀ ÊÀÏÑ. Ñ ÏÎÐ.Ä/ÈÍÃ. 18ÌÊÃ ¹30 (BOEHRINGER INGELHEIM, ÃÅÐÌÀÍÈß)BOEHRINGER INGELHEIM2479.58
ÑÏÈÐÈÂÀ ÊÀÏÑ. Ñ ÏÎÐ.Ä/ÈÍÃ. 18ÌÊÃ ¹30+ÈÍÃÀËßÒÎÐ (BOEHRINGER INGELHEIM, ÃÅÐÌÀÍÈß)BOEHRINGER INGELHEIM2394.64
ÑÏÈÐÒ ÝÒÈËÎÂÛÉ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ.È ËÅÊ.ÔÎÐÌ 70% 100ÌË ¹1 (ÊÎÍÑÒÀÍÒÀ - ÔÀÐÌ, ÐÎÑÑÈß)ÊÎÍÑÒÀÍÒÀ - ÔÀÐÌ10.19
ÑÏÈÐÒ ÝÒÈËÎÂÛÉ Ð-Ð Ä/ÍÀÐÓÆÍ.ÏÐÈÌ.È ËÅÊ.ÔÎÐÌ 95% 100ÌË ¹1 (ÊÎÍÑÒÀÍÒÀ - ÔÀÐÌ, ÐÎÑÑÈß)ÊÎÍÑÒÀÍÒÀ - ÔÀÐÌ10.76
ÑÏÈÐÓËÈÍÀ ÂÝË ¹120 (Â-ÌÈÍ/ÝÊÎËÎÃÈß ÏÈÒÀÍÈß ÍÏÎ ÇÀÎ, ÐÎÑÑÈß)Â-ÌÈÍ/ÝÊÎËÎÃÈß ÏÈÒÀÍÈß ÍÏÎ ÇÀÎ192.5
ÑÏÈÐÓËÈÍÀ ÂÝË ¹60 (ÝÊÎËÎÃÈß ÏÈÒÀÍÈß ÍÏÎ ÇÀÎ, ÐÎÑÑÈß)ÝÊÎËÎÃÈß ÏÈÒÀÍÈß ÍÏÎ ÇÀÎ110.19
ÑÏËÀÒ JUNIOR ÇÀÏÀÄ Ç/Ï Ä/Ä 55ÌË (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ101.37
ÑÏËÀÒ JUNIOR ÑÅÂÅÐ Ç/Ï Ä/Ä 55ÌË (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ101.51
ÑÏËÀÒ JUNIOR ÞÃ Ç/Ï Ä/Ä 55ÌË (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ100.03
ÑÏËÀÒ PROFESSIONAL DENTALLFLOSS ÇÓÁ. ÍÈÒÜ ÂÎËÎÊÍÀ ÑÅÐÅÁÐÀ 30Ì (ÔÑ-604) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ/PROFIMED S.R.L, ÈÒÀËÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ/PROFIMED S.R.L83.44
ÑÏËÀÒ PROFESSIONAL Ç/Ï ÀÊÒÈÂ 100ÌË (À-113) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ65.42
ÑÏËÀÒ PROFESSIONAL Ç/Ï ÀÐÊÒÈÊÓÌ 100ÌË (ÀÊ-129) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ87.77
ÑÏËÀÒ PROFESSIONAL Ç/Ï ÀÐÎÌÀÒÅÐÀÏÈß 100ÌË (ÀÐ-118) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ82.81
ÑÏËÀÒ PROFESSIONAL Ç/Ï ÁÈÎÊÀËÜÖÈÉ 100ÌË (Á-114) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ60.61
ÑÏËÀÒ PROFESSIONAL Ç/Ï ÁÈÎÊÀËÜÖÈÉ 40ÌË (Á-127) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ28.86
ÑÏËÀÒ PROFESSIONAL Ç/Ï ÇÅËÅÍÛÉ ×ÀÉ 100ÌË (Ç-117) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ72.93
ÑÏËÀÒ PROFESSIONAL Ç/Ï ËÅ×ÅÁÍÛÅ ÒÐÀÂÛ 100ÌË (ËÒ-116) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ60.12
ÑÏËÀÒ PROFESSIONAL Ç/Ï ËÈÊÂÓÌ-ÃÅËÜ 100ÌË (ËÃ-119) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ41.88
ÑÏËÀÒ PROFESSIONAL Ç/Ï ÎÒÁÅËÈÂÀÍÈÅ ÏËÞÑ 100ÌË (Î-120) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ61.87
ÑÏËÀÒ PROFESSIONAL Ç/Ï ÎÒÁÅËÈÂÀÍÈÅ ÏËÞÑ 40ÌË (Î-126) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ29.48
ÑÏËÀÒ PROFESSIONAL Ç/Ï ÓËÜÒÐÀÊÎÌÏËÅÊÑ 40ÌË (Ó-128) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ29.04
ÑÏËÀÒ SPECIAL Ç/Ï ÌÅ×ÒÀ 75ÌË (Ì-130) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ124.55
ÑÏËÀÒ SPECIAL Ç/Ï ÌÎÐÑÊÈÅ ÌÈÍÅÐÀËÛ 75ÌË (S-107) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ94.67
ÑÏËÀÒ SPECIAL Ç/Ï ÑÈÁÈÐÑÊÈÅ ßÃÎÄÛ 75ÌË (Ñß-132) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ126.96
ÑÏËÀÒ SPECIAL Ç/Ï ×ÅÐÍÎÅ ÄÅÐÅÂÎ 75ÌË (×Ä-131) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ128.15
ÑÏËÀÒ SPECIAL Ç/Ï ÝÊÑÒÐÀ ÎÒÁÅËÈÂÀÍÈÅ 75ÌË (ÝÎ-112) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ132.27
ÑÏËÀÒ SPECIAL ÎÏÎËÀÑÊÈÂÀÒÅËÜ ÎÐÃÀÍÈÊ 340ÌË (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ81.64
ÑÏËÀÒ Ç/Ï ×ÈËÈ 75ÌË (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ÐÎÑÑÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ92.99
ÑÏËÀÒ ÇÓÁÍÀß ÙÅÒÊÀ ÈÎÍÍÀß SPLAT ION SMART+ ÑÌÅÍ. ÍÀÑÀÄÊÀ (ÈÙ-606) (ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ, ßÏÎÍÈß)ÑÏËÀÒ-ÊÎÑÌÅÒÈÊÀ314.87
ÑÏÐÅÃÀËÜ ÑÏÐÅÉ 152Ã ¹1 (LABORATOIRES OMEGA PHARMA FRAN/S.C.A.T, ÔÐÀÍÖÈß)LABORATOIRES OMEGA PHARMA FRAN/S.C.A.T445.94
ÑÏÐÅÉ ÏÈÒÀÍÈÅ ÄËß ÊÎÐÍÅÉ ÂÎËÎÑ Ñ ÖÈÍÊÎÌ È ÑÅËÅÍÎÌ 150ÌË ¹1 (ËÅÊÎÌÀÊÑ ÔÀÐÌÀ, ÐÎÑÑÈß)ËÅÊÎÌÀÊÑ ÔÀÐÌÀ117.98
ÑÏÐÅÉ-ÁÀËÜÇÀÌ ÀÊÒÈÂÍÎÅ ÂÎÑÑÒÀÍÎÂËÅÍÈÅ ÂÎËÎÑ 150ÌË ¹1 (ËÅÊÎÌÀÊÑ ÔÀÐÌÀ, ÐÎÑÑÈß)ËÅÊÎÌÀÊÑ ÔÀÐÌÀ105.33
ÑÏÐÅÉ-ÁÀËÜÇÀÌ ÂÈÒÀÌÈÍÛ ÐÎÑÒÀ ÂÎËÎÑ 150ÌË ¹1 (ËÅÊÎÌÀÊÑ ÔÀÐÌÀ, ÐÎÑÑÈß)ËÅÊÎÌÀÊÑ ÔÀÐÌÀ105.03
ÑÏÐÈÍÖÎÂÊÀ ÏÂÕ Á ¹6 (Ñ ÄÂÓÌß ÍÀÊÎÍ.) (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß)ÀËÜÔÀÏËÀÑÒÈÊ20.8
ÑÏÐÈÍÖÎÂÊÀ ÏÂÕ Á ¹9 (Ñ ÄÂÓÌß ÍÀÊÎÍ.) (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß)ÀËÜÔÀÏËÀÑÒÈÊ32.47
ÑÏÐÈÍÖÎÂÊÀ ÐÅÇÈÍÎÂÀß À (ÌßÃÊ. ÍÀÊÎÍ.) ¹1 (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß)ÀËÜÔÀÏËÀÑÒÈÊ17.34
ÑÏÐÈÍÖÎÂÊÀ ÐÅÇÈÍÎÂÀß À (ÌßÃÊ. ÍÀÊÎÍ.) ¹3 (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß)ÀËÜÔÀÏËÀÑÒÈÊ28.77
ÑÐÅÄÑÒÂÎ SOS Ä/ÏÐÎÁË. ÊÎÆÈ ÌÃÍÎÂÅÍ. ÄÅÉÑÒÂÈß 15ÌË (ÝÂÈÍÀËÜ ÎÎÎ, ÐÎÑÑÈß)ÝÂÈÍÀËÜ ÎÎÎ120
ÑÒÀÊÀÍ×ÈÊ ÌÅÐÍÛÉ ÔÝÑÒ Ä/ÄÎÇÈÐÎÂÀÍÍÎÃÎ ÏÐÈÅÌÀ ËÅÊÀÐÑÒ ¹1 (ÏÐÅÄÏÐÈßÒÈÅ ÔÝÑÒ, ÐÎÑÑÈß)ÏÐÅÄÏÐÈßÒÈÅ ÔÝÑÒ1.38
ÑÒÈÇÀÌÅÒ ÌÀÇÜ 3% 35Ã ¹1 (ÐÅÒÈÍÎÈÄÛ, ÐÎÑÑÈß)ÐÅÒÈÍÎÈÄÛ67.68
ÑÒÈÌÎË Ð-Ð Ä/ÂÍÓÒÐ.ÏÐÈÌ. 10ÌË ¹18 (BIOCODEX, ÔÐÀÍÖÈß)BIOCODEX273.55
ÑÒÎÄÀËÜ ÑÈÐÎÏ 200ÌË ¹1 (BOIRON LABORATORIES, ÔÐÀÍÖÈß)BOIRON LABORATORIES143.55
ÑÒÎÌÀÒÎÔÈÒ À Ð-Ð Ä/ÌÅÑÒÍ.ÏÐÈÌ. 25Ã ¹1 (PHYTOPHARM KLENKA, ÏÎËÜØÀ)PHYTOPHARM KLENKA112.21
ÑÒÎÌÀÒÎÔÈÒ Ð-Ð Ä/ÌÅÑÒÍ.ÏÐÈÌ. 120ÌË ¹1 (PHYTOPHARM KLENKA, ÏÎËÜØÀ)PHYTOPHARM KLENKA150.24
ÑÒÎÌÀÒÎÔÈÒ Ð-Ð Ä/ÌÅÑÒÍ.ÏÐÈÌ. 45ÌË ¹1 (PHYTOPHARM KLENKA, ÏÎËÜØÀ)PHYTOPHARM KLENKA93.03
ÑÒÎÏÀÍÃÈÍ ÀÝÐÎÇÎËÜ 30ÌË ¹1 (IVAX-CR/GALENA, ×ÅÕÈß)IVAX-CR/GALENA118.68
ÑÒÎÏÀÍÃÈÍ Ð-Ð Ä/ÌÅÑÒÍ.ÏÐÈÌ. 100ÌË ¹1 (IVAX-CR, ×ÅÕÈß)IVAX-CR69.54
ÑÒÎÏÀÍÃÈÍ Ð-Ð Ä/ÌÅÑÒÍ.ÏÐÈÌ. 100ÌË ¹1 (IVAX-CR/GALENA, ×ÅÕÈß)IVAX-CR/GALENA68.3
ÑÒÎÏÀÐÒÐÎÇ 3,6Ã ÑÀØÅ ¹ 20 (SLAVIA FARM S.R.L., ÐÓÌÛÍÈß)SLAVIA FARM S.R.L.523.77
ÑÒÎÏÒÓÑÑÈÍ ÊÀÏËÈ 10ÌË ¹1 (IVAX-CR, ×ÅÕÈß)IVAX-CR45.32
ÑÒÎÏÒÓÑÑÈÍ ÊÀÏËÈ 25ÌË ¹1 (IVAX-CR, ×ÅÕÈß)IVAX-CR87.36
ÑÒÎÏÒÓÑÑÈÍ ÊÀÏËÈ 50ÌË ¹1 (IVAX-CR, ×ÅÕÈß)IVAX-CR143.88
ÑÒÎÏÒÓÑÑÈÍ ÒÀÁ. ¹20 (IVAX-CR, ×ÅÕÈß)IVAX-CR83.56
ÑÒÎÏÒÓÑÑÈÍ-ÔÈÒÎ ÑÈÐÎÏ 100ÌË ¹1 (IVAX-CR, ×ÅÕÈß)IVAX-CR83.65
ÑÒÐÀÒÒÅÐÀ ÊÀÏÑ. 18ÌÃ ¹7 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß)ELI LILLY906.27
ÑÒÐÀÒÒÅÐÀ ÊÀÏÑ. 25ÌÃ ¹7 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß)ELI LILLY906.27
ÑÒÐÀÒÒÅÐÀ ÊÀÏÑ. 25ÌÃ ¹7 (ELI LILLY, ÈÑÏÀÍÈß)ELI LILLY908.86
ÑÒÐÀÒÒÅÐÀ ÊÀÏÑ. 40ÌÃ ¹7 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß)ELI LILLY906.27
ÑÒÐÀÒÒÅÐÀ ÊÀÏÑ. 60ÌÃ ¹7 (ELI LILLY, ÂÅËÈÊÎÁÐÈÒÀÍÈß)ELI LILLY906.38
ÑÒÐÅÇÀÌ ÊÀÏÑ. 50ÌÃ ¹24 (BIOCODEX, ÔÐÀÍÖÈß)BIOCODEX112.21
ÑÒÐÅÏÑÈËÑ ÏËÞÑ ÑÏÐÅÉ 20ÌË ¹1 (BCM LTD, ÂÅËÈÊÎÁÐÈÒÀÍÈß)BCM LTD255.05
ÑÒÐÅÏÑÈËÑ ÏËÞÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹24 (RECKITT BENCKISER HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß)RECKITT BENCKISER HEALTHCARE137.18
ÑÒÐÅÏÑÈËÑ Ñ ÂÈÒÀÌÈÍÎÌ Ñ ÒÀÁ. ¹36 (ÀÏÅËÜÑÈÍ) (RECKITT BENCKISER, ÂÅËÈÊÎÁÐÈÒÀÍÈß)RECKITT BENCKISER119.84
ÑÒÐÅÏÑÈËÑ Ñ ÂÈÒÀÌÈÍÎÌ Ñ ÒÀÁ. Ä/ÐÀÑÑ. ¹24 (ÀÏÅËÜÑÈÍ) (RECKITT BENCKISER/BOOTS HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß)RECKITT BENCKISER/BOOTS HEALTHCARE74.7
ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹10 (ÌÅÄ-ËÈÌÎÍ) (RECKITT BENCKISER, ÂÅËÈÊÎÁÐÈÒÀÍÈß)RECKITT BENCKISER72.36
ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹24 (RECKITT BENCKISER HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß)RECKITT BENCKISER HEALTHCARE73.11
ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹24 (ÌÅÄ-ËÈÌÎÍ) (RECKITT BENCKISER/BOOTS HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß)RECKITT BENCKISER/BOOTS HEALTHCARE82.28
ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹24 (ÌÅÍÒ.-ÝÂÊÀË.) (RECKITT BENCKISER/BOOTS HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß)RECKITT BENCKISER/BOOTS HEALTHCARE98.97
ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹24 (ÎÐÈÃÈÍ.) (RECKITT BENCKISER, ÂÅËÈÊÎÁÐÈÒÀÍÈß)RECKITT BENCKISER75.25
ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. ¹36 (ÌÅÄ-ËÈÌÎÍ) (RECKITT BENCKISER/BOOTS HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß)RECKITT BENCKISER/BOOTS HEALTHCARE119.62
ÑÒÐÅÏÑÈËÑ ÒÀÁ. Ä/ÐÀÑÑ. Á/ÑÀÕ. ¹24 (ËÈÌÎÍ) (RECKITT BENCKISER HEALTHCARE, ÂÅËÈÊÎÁÐÈÒÀÍÈß)RECKITT BENCKISER HEALTHCARE111.64
ÑÒÐÅÏÒÎÊÈÍÀÇÀ ËÈÎÔ.ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍ. 1500000 ÌÅ ¹1 (ÁÅËÌÅÄÏÐÅÏÀÐÀÒÛ ÐÓÏ, ÁÅËÀÐÓÑÜ)ÁÅËÌÅÄÏÐÅÏÀÐÀÒÛ ÐÓÏ11321.65
ÑÒÐÅÏÒÎÌÈÖÈÍ ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍ. 1Ã ¹1 (ÑÈÍÒÅÇ ÀÊÎÌÏ, ÐÎÑÑÈß)ÑÈÍÒÅÇ ÀÊÎÌÏ6.08
ÑÒÐÅÏÒÎÖÈÄ ËÈÍÈÌÅÍÒ 5% 30Ã ¹1 (ÍÈÆÔÀÐÌ, ÐÎÑÑÈß)ÍÈÆÔÀÐÌ30.36
ÑÒÐÅÏÒÎÖÈÄ ÏÎÐ.Ä/ÍÀÐÓÆÍ.ÏÐÈÌ. 2Ã ¹1 (ËÞÌÈ, ÐÎÑÑÈß)ËÞÌÈ1.21
ÑÒÐÅÏÒÎÖÈÄ ÏÎÐ.Ä/ÍÀÐÓÆÍ.ÏÐÈÌ. 2Ã ¹1 (ÌÎÑÊÎÂÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÌÎÑÊÎÂÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ1.76
ÑÒÐÅÏÒÎÖÈÄ ÏÎÐ.Ä/ÍÀÐÓÆÍ.ÏÐÈÌ. 2Ã ¹1 (ÒÓËÜÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ, ÐÎÑÑÈß)ÒÓËÜÑÊÀß ÔÀÐÌ.ÔÀÁÐÈÊÀ2.19
ÑÒÐÅÏÒÎÖÈÄ ÏÎÐ.Ä/ÍÀÐÓÆÍ.ÏÐÈÌ. 2Ã ¹1 (ÔÀÐÌÍÎÂÀÖÈß, ÐÎÑÑÈß)ÔÀÐÌÍÎÂÀÖÈß1.17
ÑÒÐÅÏÒÎÖÈÄÎÂÀß ÌÀÇÜ ÌÀÇÜ 10% 25Ã ¹1 (ÁÈÎÑÈÍÒÅÇ, ÐÎÑÑÈß)ÁÈÎÑÈÍÒÅÇ26.12
ÑÒÐÈÊÑ ÊÈÄÑ ÒÀÁ. ÆÅÂ. ¹30 (FERROSAN, ÄÀÍÈß)FERROSAN264.72
ÑÒÐÈÊÑ ÒÀÁ. ¹30 (FERROSAN, ÄÀÍÈß)FERROSAN274
ÑÒÐÈÊÑ ÔÎÐÒÅ ÒÀÁ. ¹30 (FERROSAN, ÄÀÍÈß)FERROSAN413.25
ÑÒÐÎÔÀÍÒÈÍ Ê Ð-Ð Ä/ÈÍ. 0,025% 1ÌË ¹10 (ÃÀËÈ×ÔÀÐÌ ÀÎ, ÓÊÐÀÈÍÀ)ÃÀËÈ×ÔÀÐÌ ÀÎ16.68
ÑÒÐÓÊÒÓÌ ÊÀÏÑ. 500ÌÃ ¹60 (PIERRE FABRE/ÑÎÒÅÊÑ, ÐÎÑÑÈß)PIERRE FABRE/ÑÎÒÅÊÑ1053.98
ÑÒÓÃÅÐÎÍ ÒÀÁ. 25ÌÃ ¹50 (GEDEON RICHTER, ÂÅÍÃÐÈß)GEDEON RICHTER69.23
ÑÓÄÍÎ ÏÎÄÊËÀÄÍÎÅ ÏÎËÈÌÅÐÍÎÅ ËÀÄÜß ¹1 (ÌÅÄÏÎËÈÌÅÐÒÎÐÃ, ÐÎÑÑÈß)ÌÅÄÏÎËÈÌÅÐÒÎÐÃ121.57
ÑÓÄÍÎ ÏÎÄÊËÀÄÍÎÅ ÐÅÇÈÍÎÂÎÅ ¹1 (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß)ÀËÜÔÀÏËÀÑÒÈÊ267.77
ÑÓÄÍÎ ÏÎÄÊËÀÄÍÎÅ ÐÅÇÈÍÎÂÎÅ ¹2 (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß)ÀËÜÔÀÏËÀÑÒÈÊ207.78
ÑÓÄÍÎ ÏÎÄÊËÀÄÍÎÅ ÐÅÇÈÍÎÂÎÅ ¹3 (ÀËÜÔÀÏËÀÑÒÈÊ, ÐÎÑÑÈß)ÀËÜÔÀÏËÀÑÒÈÊ230.55
ÑÓÊÐÀÇÈÒ ÒÀÁ. ¹1200 (BISCOL CO. LTD, ÈÇÐÀÈËÜ)BISCOL CO. LTD85.59
ÑÓËÜÃÈÍ ÒÀÁ. 500ÌÃ ¹10 (ÈÐÁÈÒÑÊÈÉ ÕÔÇ, ÐÎÑÑÈß)ÈÐÁÈÒÑÊÈÉ ÕÔÇ16.12
ÑÓËÜÏÅÐÀÇÎÍ ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍ. 2Ã ¹1 (PFIZER, ÒÓÐÖÈß)PFIZER388.42
ÑÓËÜÏÈÐÈÄ ÒÀÁ. 200ÌÃ ¹30 (ÎÐÃÀÍÈÊÀ, ÐÎÑÑÈß)ÎÐÃÀÍÈÊÀ46.2
ÑÓËÜÏÈÐÈÄ ÒÀÁ. 50ÌÃ ¹30 (ÎÐÃÀÍÈÊÀ, ÐÎÑÑÈß)ÎÐÃÀÍÈÊÀ53.93
ÑÓËÜÒÀÑÈÍ ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍ. 1,5Ã ¹1 (ÑÈÍÒÅÇ, ÐÎÑÑÈß)ÑÈÍÒÅÇ28.75
ÑÓËÜÔÀÄÈÌÅÒÎÊÑÈÍ ÒÀÁ. 500ÌÃ ¹10 (ÁÈÎÑÈÍÒÅÇ, ÐÎÑÑÈß)ÁÈÎÑÈÍÒÅÇ12.04
ÑÓËÜÔÀÄÈÌÅÒÎÊÑÈÍ ÒÀÁ. 500ÌÃ ¹10 (ÁÈÎÕÈÌÈÊ ÎÀÎ, ÐÎÑÑÈß)ÁÈÎÕÈÌÈÊ ÎÀÎ14.1
ÑÓËÜÔÀÑÀËÀÇÈÍ ÒÀÁ. Ï/Î 500ÌÃ ¹50 (KRKA, ÑËÎÂÅÍÈß)KRKA236.33
ÑÓËÜÔÀÑÀËÀÇÈÍ-ÅÍ ÒÀÁ. Ï/Î 500ÌÃ ¹50 (KRKA, ÑËÎÂÅÍÈß)KRKA243.04
ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ ÊÀÏËÈ ÃËÀÇÍÛÅ 20% 1,5ÌË ¹2 ÒÞÁ.-ÊÀÏ. (ÌÎÑÊÎÂÑÊÈÉ ÝÍÄÎÊÐÈÍÍÛÉ ÇÀÂÎÄ, ÐÎÑÑÈß)ÌÎÑÊÎÂÑÊÈÉ ÝÍÄÎÊÐÈÍÍÛÉ ÇÀÂÎÄ14.87
ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ ÊÀÏËÈ ÃËÀÇÍÛÅ 20% 10ÌË ¹1 ÔË.-ÊÀÏ. (ÑËÀÂßÍÑÊÀß ÀÏÒÅÊÀ, ÐÎÑÑÈß)ÑËÀÂßÍÑÊÀß ÀÏÒÅÊÀ8.48
ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ ÊÀÏËÈ ÃËÀÇÍÛÅ 20% 1ÌË ¹2 ÒÞÁ.-ÊÀÏ. (ÁÅËÌÅÄÏÐÅÏÀÐÀÒÛ ÐÓÏ, ÁÅËÀÐÓÑÜ)ÁÅËÌÅÄÏÐÅÏÀÐÀÒÛ ÐÓÏ16.96
ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ ÊÀÏËÈ ÃËÀÇÍÛÅ 20% 5ÌË ¹1 ÔË.-ÊÀÏ. (ÑÈÍÒÅÇ, ÐÎÑÑÈß)ÑÈÍÒÅÇ13.64
ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ ÊÀÏËÈ ÃËÀÇÍÛÅ 20% 5ÌË ¹1 ÔË.-ÊÀÏ. (ÑËÀÂßÍÑÊÀß ÀÏÒÅÊÀ, ÐÎÑÑÈß)ÑËÀÂßÍÑÊÀß ÀÏÒÅÊÀ7.17
ÑÓËÜÔÀÖÈË-ÍÀÒÐÈÉ-ÄÈÀ ÊÀÏËÈ ÃËÀÇÍÛÅ 20% 5ÌË ¹1 (ÄÈÀÔÀÐÌ, ÐÎÑÑÈß)ÄÈÀÔÀÐÌ5.97
ÑÓËÜÔÎÄÅÊÎÐÒÝÌ ÌÀÇÜ 25Ã ¹1 (ÍÈÆÔÀÐÌ, ÐÎÑÑÈß)ÍÈÆÔÀÐÌ25.65
ÑÓËÜÔÎÊÀÌÔÎÊÀÈÍ Ð-Ð Ä/ÈÍ. 10% 2ÌË ¹10 (ÓÔÀÂÈÒÀ, ÐÎÑÑÈß)ÓÔÀÂÈÒÀ52.63
ÑÓËÜÔÎÊÀÌÔÎÊÀÈÍ Ð-Ð Ä/ÈÍ. 10% 2ÌË ¹10 (ÔÀÐÌÑÒÀÍÄÀÐÒ-ÓÔÀÂÈÒÀ, ÐÎÑÑÈß)ÔÀÐÌÑÒÀÍÄÀÐÒ-ÓÔÀÂÈÒÀ54.66
ÑÓÌÀÌÅÄ ËÈÎÔ.ÏÎÐ.Ä/ÏÐÈÃ.Ð-ÐÀ Ä/ÈÍÔ. 500ÌÃ ¹5 (PLIVA, ÕÎÐÂÀÒÈß)PLIVA1610.88
ÑÓÌÀÌÅÄ ÏÎÐ.Ä/ÏÐÈÃ.ÑÓÑÏ.Ä/ÂÍÓÒÐ.ÏÐÈÌ. 100ÌÃ / 5ÌË 17Ã 23ÌË ¹1 (PLIVA, ÕÎÐÂÀÒÈß)PLIVA184.1
ÑÓÌÀÌÅÄ ÒÀÁ. 125ÌÃ ¹6 (PLIVA, ÕÎÐÂÀÒÈß)PLIVA283.35
ÑÓÌÀÌÅÄ ÒÀÁ. 500ÌÃ ¹3 (PLIVA, ÕÎÐÂÀÒÈß)PLIVA426.47
ÑÓÌÀÌÅÄ ÔÎÐÒÅ ÏÎÐ.Ä/ÏÐÈÃ.ÑÓÑÏ.Ä/ÂÍÓÒÐ.ÏÐÈÌ. 200ÌÃ / 5ÌË 20ÌË ¹1 (PLIVA, ÕÎÐÂÀÒÈß)PLIVA307.25
ÑÓÌÀÌÈÃÐÅÍ ÒÀÁ. Ï/Î 100ÌÃ ¹2 (POLPHARMA, ÏÎËÜØÀ)POLPHARMA266.61
ÑÓÌÀÌÈÃÐÅÍ ÒÀÁ. Ï/Î 50ÌÃ ¹2 (POLPHARMA, ÏÎËÜØÀ)POLPHARMA156.47
ÑÓÌÀÕ ÊÐÅÌ Ä/ÒÅËÀ 75ÌË (ÎÇÄÎÐÎÂÈÒÅËÜÍÛÅ ÁÈÎÒÅÕÍÎËÎÃÈÈ, ÐÎÑÑÈß)ÎÇÄÎÐÎÂÈÒÅËÜÍÛÅ ÁÈÎÒÅÕÍÎËÎÃÈÈ92.39
ÑÓÏÅÐ×ÈÑÒÎÒÅË 1,2ÌË (ÀÑÏÅÐÀ, ÐÎÑÑÈß)ÀÑÏÅÐÀ12.17
ÑÓÏÅÐ×ÈÑÒÎÒÅË 3,6ÌË (ÀÑÏÅÐÀ, ÐÎÑÑÈß)ÀÑÏÅÐÀ13.41
ÑÓÏÐÀÄÈÍ ÒÀÁ. ¹30 (HOFFMANN LA ROCHE, ÔÐÀÍÖÈß)HOFFMANN LA ROCHE345.66
ÑÓÏÐÀÄÈÍ ÒÀÁ. ØÈÏÓ×ÈÅ ¹10 (BAYER SANTE FAMILIALE, ÔÐÀÍÖÈß)BAYER SANTE FAMILIALE172.07
ÑÓÏÐÀÊÑ ÃÐÀÍÓËÛ Ä/ÏÐÈÃ.ÑÓÑÏ.Ä/ÂÍÓÒÐ.ÏÐÈÌ. 100ÌÃ/5ÌË 30Ã ¹1 (HIKMA PHARMACEUTICALS/GEDEON RICHTER, ÈÎÐÄÀÍÈß/ÐÎÑÑÈß)HIKMA PHARMACEUTICALS/GEDEON RICHTER365.1
ÑÓÏÐÀÊÑ ÊÀÏÑ. 400ÌÃ ¹6 (HIKMA PHARMACEUTICALS/GEDEON RICHTER, ÐÎÑÑÈß)HIKMA PHARMACEUTICALS/GEDEON RICHTER513.71
ÑÓÏÐÀÑÒÈÍ Ð-Ð Ä/ÈÍ. 2% 1ÌË ¹5 (EGIS, ÂÅÍÃÐÈß)EGIS118.6
ÑÓÏÐÀÑÒÈÍ ÒÀÁ. 25ÌÃ ¹20 (EGIS, ÂÅÍÃÐÈß)EGIS102.2
ÑÓÏÐÅÍÀÌÈÍ ÒÀÁ. Ï/Î ¹20Õ2 (ÊËÈÍÈÊÀ ÈÍÑÒÈÒÓÒÀ ÃÅÐÎÍÒÎËÎÃÈÈ, ÐÎÑÑÈß)ÊËÈÍÈÊÀ ÈÍÑÒÈÒÓÒÀ ÃÅÐÎÍÒÎËÎÃÈÈ237.89
ÑÓÏÐÈÌÀ-ÏËÞÑ ÌÀÇÜ 20Ã ¹1 (SHREYA LIFE, ÈÍÄÈß)SHREYA LIFE45.07
ÑÓÑÒÀÍÎÍ-250 Ð-Ð ÄËß Â/Ì ÂÂÅÄ. 1ÌË ¹1 (ORGANON, ÍÈÄÅÐËÀÍÄÛ)ORGANON600.83
ÑÓÑÒÀÑÒÈÍ ÁÀËÜÇÀÌ Ä/ÑÓÑÒÀÂΠ75ÌË (ÈÑÒÎ×ÍÈÊ ÄÎËÃÎËÅÒÈß, ÐÎÑÑÈß)ÈÑÒÎ×ÍÈÊ ÄÎËÃÎËÅÒÈß57.11
ÑÓØÅÍÈÖÀ ÒÎÏßÍÀß 35à ¹1 (ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ, ÐÎÑÑÈß)ÔÈÒÎ-ÝÌ ÇÀÎ ÀÏÔ23.29
ÑÛÂÎÐÎÒÊÀ ÌÓËÜÒÈÀÊÒ. INTENSIVE WAY 24 ÌÎÄÅËÈÐ. ÆÈÂÎÒ È ßÃÎÄ. 150ÌË (ËÈÍÄÀ ÏÊÔ ÎÎÎ, ÐÎÑÑÈß)ËÈÍÄÀ ÏÊÔ ÎÎÎ57.16
ÑÛÂÎÐÎÒÊÀ Ñ ÝÊÑÒÐ. ÏËÀÖ. ÎÌÎËÀÆ. Ä/ÊÎÆÈ ÂÎÊÐÓÃ ÃËÀÇ 15ÌË (ÝÂÈÍÀËÜ ÎÎÎ, ÐÎÑÑÈß)ÝÂÈÍÀËÜ ÎÎÎ241.2
ÑÛÂÎÐÎÒÊÀ Ñ ÝÊÑÒÐ. ÏËÀÖ. ÎÌÎËÀÆ. Ä/ÊÎÆÈ ËÈÖÀ 30ÌË (ÝÂÈÍÀËÜ ÎÎÎ, ÐÎÑÑÈß)ÝÂÈÍÀËÜ ÎÎÎ227.48
ÑÛÂÎÐÎÒÊÀ Ñ ÝÊÑÒÐ. ÏËÀÖ. ÐÅÃÅÍ. È ÓÊÐÅÏË. Ä/ÂÎËÎÑ 150ÌË (ÝÂÈÍÀËÜ ÎÎÎ, ÐÎÑÑÈß)ÝÂÈÍÀËÜ ÎÎÎ135.96
ÑÛÂÎÐÎÒÊÀ Ñ ÝÊÑÒÐ. ÏËÀÖ. ÐÅÃÅÍ. ÊÎÑÌÅÒÈ×. Ä/ÊÎÆÈ ÂÎÊÐÓà ÃËÀÇ 15ÌË (COSMEDIC LABORATORY, ÐÎÑÑÈß)COSMEDIC LABORATORY178.02
ÑÛÂÎÐÎÒÊÀ Ñ ÝÊÑÒÐ. ÏËÀÖ. ÐÅÃÅÍ. ÓÍÈÂÅÐÑÀËÜÍÀß 50ÌË (COSMEDIC LABORATORY, ÐÎÑÑÈß)COSMEDIC LABORATORY160.25





2001-2011 http://www.med.sgg.ru - öåíû íà ëåêàðñòâà, ìåäòåõíèêó, âñå äëÿ ñòîìàòîëîãèè, õèðóðãè÷åñêèé è äðóãîé ìåäèöèíñêèé èíñòðóìåíò è òåõíèêà, ôàðìàöåâòè÷åñêèå ïðåïàðàòû è ñóáñòàíöèè îò ïðîèçâîäèòåëåé è îïòîâûõ ïðîäàâöîâ â Ìîñêâå, Ñàíêò-Ïåòåðáóðãå è äðóãèõ ðåãèîíàõ.



Rambler's Top100 Rambler's Top100 Ðåéòèíã@Mail.ru